CIMETIDINE 400 MG — DIN 00600059
CIMETIDINE : 400 MG · AA PHARMA INC · TABLET · wholesale supply in Canada
Health Canada status: DORMANT
What is CIMETIDINE?
CIMETIDINE 400 MG contains CIMETIDINE : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 00600059, held by AA PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 23-Jan-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is CIMETIDINE used for?
Duodenal/gastric ulcer therapy and prophylaxis; GERD; pathological hypersecretion (Zollinger-Ellison); NSAID-induced lesions; adjunctive therapy for cystic fibrosis in children.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Cimetidine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
15 holders have a Canadian DIN containing Cimetidine, across 50 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AA PHARMA INC | 5 | 2 | CIMETIDINE | Sourceable in Canada |
| TEVA CANADA LIMITED | 6 | 0 | NOVO-CIMETINE, NOVO-CIMETINE INJECTION | No marketed DIN |
| CARTER-HORNER CORP. | 5 | 0 | PEPTOL TAB 200MG, PEPTOL TAB 300MG, PEPTOL TAB 400MG, PEPTOL TAB 600MG, PEPTOL TAB 800MG | No marketed DIN |
| DOMINION PHARMACAL | 5 | 0 | DOM-CIMETIDINE | No marketed DIN |
| PHARMASCIENCE INC | 5 | 0 | PMS-CIMETIDINE | No marketed DIN |
| GLAXOSMITHKLINE INC | 4 | 0 | TAGAMET 300, TAGAMET 400, TAGAMET 600, TAGAMET LIQUID 60MG/ML | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 4 | 0 | MYLAN-CIMETIDINE | No marketed DIN |
| NU-PHARM INC | 4 | 0 | NU-CIMET TAB 200MG, NU-CIMET TAB 300MG, NU-CIMET TAB 400MG, NU-CIMET TAB 600MG | No marketed DIN |
| PRO DOC LIMITEE | 4 | 0 | CIMETIDINE 200 TAB 200MG, CIMETIDINE TAB 300MG, CIMETIDINE TAB 400MG, CIMETIDINE TAB 600MG | No marketed DIN |
| GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC | 2 | 0 | GAVISCON ALL-NIGHT, GAVISCON PREVENT | No marketed DIN |
| SMITHKLINE BEECHAM PHARMA DIVISION OF SMITHKLINE BEECHAM INC | 2 | 0 | TAGAMET INFUSION 6MG/ML, TAGAMET INJ 150MG/ML | No marketed DIN |
| GENPHARM ULC | 1 | 0 | GEN-CIMETIDINE TABLETS 200MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 400 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 100, 500, and 1000 tablets (depending on strength). |
| Storage | Information not explicitly provided in the text provided (Section 11 is listed in TOC but content is missing from snippet). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Cimetidine |
|---|---|
| ATC code | A02BA01 |
| AHFS class | 56:28.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00600059 |
|---|---|
| DIN (unpadded, as printed on some documents) | 600059 |
| Brand name | CIMETIDINE |
| Generic / active ingredient | CIMETIDINE : 400 MG |
| Market authorization holder | AA PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | A02BA01 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A02BA |
| Current status | DORMANT |
| Status date | 23-Jan-2019 |
| Original market date | 1983-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 800-1200 mg/day for ulcers; 1.2 g/day for GERD; 300 mg qid for hypersecretion. May be given as once daily at bedtime, twice daily, or four times daily. Adjust dose in renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to the drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Symptomatic response does not preclude gastric malignancy; treatment may mask symptoms of gastric cancer. Use with caution in elderly/severely ill due to risk of confusional states.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 50 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CIMETIDINE | 300 MG | TABLET | AA PHARMA INC | MARKETED | 00487872 |
| CIMETIDINE | 200 MG | TABLET | AA PHARMA INC | MARKETED | 00584215 |
| APO-CIMETIDINE ORAL SOLUTION | 300 MG / 5 ML | LIQUID | APOTEX INC | CANCELLED POST MARKET | 02243085 |
| CIMETIDINE | 600 MG | TABLET | AA PHARMA INC | DORMANT | 00600067 |
| CIMETIDINE | 800 MG | TABLET | AA PHARMA INC | DORMANT | 00749494 |
| CIMETIDINE 200 TAB 200MG | 200 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | 00596469 |
| CIMETIDINE TAB 300MG | 300 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | 00596477 |
| CIMETIDINE TAB 400MG | 400 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | 00618691 |
| CIMETIDINE TAB 600MG | 600 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | 00618705 |
| DOM-CIMETIDINE | 200 MG | TABLET | DOMINION PHARMACAL | CANCELLED PRE MARKET | 02231285 |
2 · Same class — other molecules in ATC A02BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Famotidine | ACID CONTROL · ACID CONTROLLER MAXIMUM STRENGTH · ACT · AG-FAMOTIDINE · +39 more | 68 | 17 | Yes |
| Ranitidine | ACID REDUCER · ACID REDUCER MAXIMUM STRENGTH NON-PRESCRIPTION · ACT RANITIDINE · AG-RANITIDINE · +46 more | 96 | 5 | Yes |
| Cimetidine | APO-CIMETIDINE ORAL SOLUTION · CIMETIDINE · CIMETIDINE 200 TAB 200MG · CIMETIDINE TAB 300MG · +27 more | 50 | 2 | Yes |
| Nizatidine | APO-NIZATIDINE · AXID · DOM-NIZATIDINE 150MG CAPSULES · GEN-NIZATIDINE · +7 more | 19 | 1 | Yes |
| Famotidine, Combinations | PEPCID COMPLETE | 1 | 1 | Yes |
| Ranitidine Bismuth Citrate | PYLORID | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A02B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A02BC | Dexlansoprazole · Esomeprazole · Lansoprazole · Omeprazole · Pantoprazole · +1 more | 288 | 108 |
| A02BX | Alginic Acid · Pirenzepine · Sucralfate | 32 | 4 |
| A02BB | Misoprostol | 10 | 2 |
| A02BD | Bismuth Subcitrate,Tetracycline And Metronidazole · Lansoprazole, Amoxicillin And Clarithromycin | 3 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CIMETIDINE called?
Also recorded in Canada as: cimetidine 200 MG Oral Tablet [Tagamet] (US), cimetidine 400 MG Effervescent Oral Tablet (US), cimetidine 200 MG Oral Tablet (US), cimetidine 300 MG Oral Tablet (US), cimetidine 400 MG Oral Tablet (US), cimetidine 800 MG Oral Tablet (US), cimetidine 100 MG Oral Tablet (US), cimetidine 60 MG/ML Oral Solution (US), cimetidine 100 MG/ML Injectable Solution (US), cimetidine 40 MG/ML Oral Suspension (US), cimetidine 10 MG/ML Oral Suspension (US), cimetidine 6 MG/ML Injectable Solution (US), cimetidine 40 MG/ML Oral Solution (US), CIMETIDINE 10% / LIDOCAINE 5% / SALICYLIC ACID 40% (US), CIMETIDINE 200 ACID REDUCER (US).
What is Cimetidine called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Cimetidine, published to help those searches reach this page.
| Language | Cimetidine |
|---|---|
| Arabic العربية | سيميتيدين |
| Chinese (Simplified) 简体中文 | 西咪替丁 |
| Russian Русский | циметидин |
| Spanish Español | cimetidina |
| French Français | cimétidine |
| Portuguese Português | cimetidina |
| German Deutsch | Cimetidin |
| Turkish Türkçe | simetidin |
| Japanese 日本語 | シメチジン |
| Korean 한국어 | 시메티딘 |
| Vietnamese Tiếng Việt | cimetidin |
| Indonesian Bahasa Indonesia | simetidin |
| Hebrew עברית | סימטידין |
| Greek Ελληνικά | σιμετιδίνη |
| Polish Polski | cymetydyna |
| Italian Italiano | cimetidina |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.